Table 1.
Studies assessing the prognostic value of macrophages in OSCC
| Authors, ref. | Number of patients, tumour size/stage, inclusion period, country | Tumour compartment analysed | Direction of effect on survival high cell count | Statistical significance | |
|---|---|---|---|---|---|
| UV | MV | ||||
| Marker: CD68, pan-macrophage marker | |||||
| Sun et al.27 | 72a, Stage I–IV, 2009-2011, China | No info | Negative | OS: P = 0.034 | OS: P = 0.015 |
| Wirsing et al.28 | 75, T1–T4, 1986–2002, Norway | Stroma at tumour front | Positive | DSS: P = 0.027 | DSS: P > 0.05 |
| Fang et al.29 | 78a, Stage I–IV, 2007–2009, China | Stroma | No info | OS: P = 0.293, HR 1.364 (95% CI 0.765–2.433)b | OS: P = 0.177, HR 0.652 (95% CI 0.351–1.212)b |
| Hu et al.30 | 127, Stage I–IV, 2007–2013, China | Nest | Negative | OS: P = 0.01, RR 3.08 (95% CI 2.236–3.914) | NA |
| Stroma | Positive | OS: P = 0.3, RR .69 (95% CI −0.010–1.390) | NA | ||
| Sakakura et al.31 | 74, Stage I–IV, 2000–2012, Japan | Stroma | Negative | OS: P = 0.035 | OS: P > 0.05 |
| Ni et al.32 | 91, T1–T4, 2003–2011, China | Stroma | Negative | OS: P = 0.033, HR 1.947 (95% CI 1.512–10.379) | OS: P = 0.736, HR 1.55 (95% CI 0.122–19.515) |
| DFS: P = 0.435 | NA | ||||
| Nest | Positive | OS: P = 0.802, HR 0.904 (95% CI 0.180–4.552) | NA | ||
| DFS: P = 0.562 | NA | ||||
| Costa et al.33 | 45, T1–T4, Period missing, Brazil | Peritumour | Negative | OS: P = 0.08 | NA |
| Dayan et al.34 | 54, Stage I–IV, 1990–2006, Israel | Tumour–stroma interface | No info | OS: P > 0.05 | NA |
| Fujii et al.35 | 108, Stage I–IV, 1990–2005, Japan | Stroma at invasive front | No info. | OS: P = 0.16 | NA |
| Lu et al.36 | 92, Stage I–IV, 1995–2003, Taiwan | Stroma | Negative | OS: P < 0.001 | OS: P = 0.015 |
| DFS: P = 0.001 | DFS: P = 0.005 | ||||
| Liu et al.37 | 112a, T1–T4, Period missing, Taiwan | No info | Negative | DFS: P = 0.001 | NA |
| Marker: CD163, M2 macrophages | |||||
| Kubota et al.38 | 46, Stage I–IV, 2005–2015, Japan | Nest | Negative | PFS: P = 0.21, HR 1.53 (95% CI 0.77–3.02) | PFS: P = 0.64, HR 1.18 (95% CI 0.57–2.42) |
| DSS: P = 0.58, HR 1.22 (95% CI 0.57–2.50) | DSS: P = 0.61, HR 1.20 (95% CI 0.56–2.46) | ||||
| Hu et al.30 | 127, Stage I–IV, 2007–2013, China | Nest | Negative | OS: P = 0.02, RR 2.83 (95% CI 1.991–3.669) | NA |
| Stroma | Positive | OS: P = 0.48, RR 0.78 (95% CI 0.085–1.473) | NA | ||
| Sakakura et al.31 | 74, Stage I–IV, 2000–2012, Japan | Stroma | Negative | OS: P = 0.025 | OS: P = 0.034 |
| PFS: P = 0.011 | PFS: P = 0.023 | ||||
| Matsuoka et al.39 | 60, Stage I–IV, 2003–2009, Japan | Stroma at invasive front | Negative | OS: P = 0.003 | OS: P = 0.195, HR 2.299 (95% CI 0.657–8.737) |
| DFS: P = 0.007 | DFS: P = 0.258, HR 1.749 (95% CI 0.669–4.904) | ||||
| Fujita et al.40 | 50a, Stage I–IV, 2006–2010, Japan | Invasive front | Negative | OS: P = 0.006 | OS: NA |
| DFS: P = 0.002 | DFS: P = 0.006, HR 2.625 (95% CI 1.312–5.253) | ||||
| Intratumour | No info. | OS: P > 0.05 | NA | ||
| DFS: P > 0.05 | NA | ||||
| Wang et al.41 | 240, Stage I–IV, M0, 1982–2005, China | Stroma | Negative | OS: P < 0.001, HR 4.411 (95% CI 2.578–7.547a) | OS: P = 0.001, HR 3.561 (95% CI 1.733–7.320) |
| Dayan et al.34 | 54, Stage I–IV, 1990–2006, Israel | Tumour–stroma interface | No info | OS: P > 0.05 | NA |
| Fujii et al.35 | 108, Stage I–IV, 1990–2005, Japan | Stroma at invasive front | Negative | OS: P = 0.007 | OS: P = 0.045, HR 2.636 (95% CI 1.021–6.803) |
OS overall survival, if survival was not specified it was interpreted as overall survival, DSS disease-specific survival, PFS progression-free survival, RFS recurrence-free survival, DFS disease-free survival, HR hazards ratio, RR risk ratio, NA Not applied
Significant values are bold (p< 0.05)
aDenotes that information about chemotherapy/radiation exposure of tissue prior to surgery was missing or ambiguous
bDenotes that the HR and CI were inverted in these studies